IL6 and metabolic dysfunction-associated steatohepatitis: In the same line, treatment with BM-MSCs showed significant decrease in the cardiac levels of NF-κB, IL-6 and TNF-α by 37.6%, 38.3% and 27.9%, respectively, as compared to cardiotoxicity induced by NASH group.